Topic

Point of Contact

Code

Animal and Cellular Models:

• for rare non-malignant and pre-malignant (MDS & MPD) hematologic disorders
• for complications associated with thrombosis
• for transfusion of blood products or cell-based therapies

Phyllis Mitchell, phyllis.mitchell@nih.gov

HLS17-01

Research tools: Imaging, reagents, assays including microassays, microfluidics, bioinformatics and nanotechnology for investigations of blood diseases, transfusion and cellular therapies

Phyllis Mitchell, phyllis.mitchell@nih.gov

HLS17-02

Diagnostics: devices, biomarkers, imaging, and assays for non-malignant blood disorders

Phyllis Mitchell, phyllis.mitchell@nih.gov

HLS17-03

Therapeutics: drugs, blood product and cellular therapies, and gene therapy for non-malignant blood disorders

Phyllis Mitchell, phyllis.mitchell@nih.gov

HLS17-04

E-medicine Apps for patients and medical professionals to improve the management of and reduce the impact of non-malignant blood diseases

Phyllis Mitchell, phyllis.mitchell@nih.gov

HLS17-05

Development of molecular imaging reagents/techniques and nanotechnology-based drug delivery systems that detect and allow for specific targeting of lung diseases, such as plexiform lesions in PAH (pulmonary arterial hypertension), microvascular loci susceptible to rarefaction/pruning in obstructive airway diseases like emphysema, or fibrotic triggers in IPF (idiopathic pulmonary fibrosis).

Sara Lin, linq@nhlbi.nih.gov

HLS17-06

Development of reagents and methods to identify and isolate stem/progenitor cells, and direct differentiation to specific functional organ units. These reagents may include antibodies for stem/progenitor cell detection and sorting, biomaterials for optimizing the microniches of stem/progenitor cells, as well as methods for 3-D regeneration of tissue.

Sara Lin, linq@nhlbi.nih.gov

HLS17-07

Development and validation of techniques (or algorithms) to study the microbiome in situ, including, but not limited to:

• Sampling the microbiome of different lung or gut segments while minimizing contamination from other locations.
• Development of an analytical system to study the metabolic products of the lung and gut microbiome from breath condensate

Lis Caler, lis.caler@nih.gov

HLS17-08

Characterization and in vivo or in vitro applications of miRNA panels that target lung-resident mesenchymal or fibroblast cells and directly or indirectly promote lung repair or regeneration

Sara Lin, linq@nhlbi.nih.gov

HLS17-09

Development of high throughput methods to apply microfluidics technology in discovery of molecular profiles (DNAs, RNAs, proteins, or metabolites) in a large number of sputum or exhaled breath condensate samples collected from lung disease patients.

Lisa Postow, lisa.postow@nih.gov

HLS17-10

High-definition, conformal, biocompatible mesh technologies made from nanoscale materials are revolutionizing electronic-tissue interfaces. Applications that leverage this technology should expand or enhance the ability of present systems to monitor and treat cardiovascular and pulmonary disorders such as arrhythmias, sleep apnea, asthma, and COPD.

David Lathrop, lathropd@nhlbi.nih.gov

HLS17-11

Develop new and improved methods to assess, monitor, or predict cardiovascular toxicity of therapeutic agents. Methods or assay platforms that utilize in vitro (e.g., re-programmed cells and engineered 3D-tissue constructs) and in silico approaches are encouraged.

Bishow Adhikari, adhikarb@mail.nih.gov

HLS17-12

For citizens returning to an urban environment after release from prison or jail, develop and validate mobile app solutions they can use to improve their health outcomes related to cardiovascular diseases including but not limited to hypertension. For example, these solutions should use evidence-based guidelines for the management of cardiovascular disease such as care planning, medication management, assessment or monitoring of cardiovascular disease and decision support that includes multi-level (health systems, provider, and patient) facets. Solutions should also include user support documentation for all potential users of the technology, including but not limited to patients, family/caregivers, and providers.

Erin Iturriaga, iturriae@mail.nih.gov

HLS17-13

New animal models for the study of chronic venous insufficiency (CVI) and post-thrombotic syndrome, and innovative approaches for their prevention and treatment.

Cheryl McDonald, mcdonalc@mail.nih.gov

HLS17-14

Development of mechanical circulatory support devices for individuals with congenital heart disease and single ventricle physiology after Fontan surgical palliation.

Kristen Burns, Kristin.burns@nih.gov

HLS17-15

Novel non-invasive strategies that detect early subclinical changes in cardiac structure, function, and /or tissue are needed to improve detection and monitoring of chemotherapy-induced cardiac injury in order to improve cardioprotection and effectiveness of cancer therapeutics. Strategies that increase sensitivity and precision of existing or enhance imaging technologies with respect to normal and altered cardiac structure, function, energetics, and metabolism are sought. Pre-clinical or patient studies using molecular changes or biomarkers to enhance early detection of cardiac derangements are also responsive.

Patrice Desvigne-Nickens, Patrice.Desvignenickens@nih.gov

HLS17-16

Develop innovative technology and/or service delivery models or designs to increase the adoption, uptake, and sustainability of evidence-based guideline recommendations for the management of heart, lung, blood, and sleep disorders. These should include multi-level (health systems, provider, and patient) facets and benefit ethnic/racial minority groups, rural populations, and low socioeconomic status groups.

Uche Sampson, uchechukwu.sampson@nih.gov

HLS17-17